<DOC>
	<DOCNO>NCT03025542</DOCNO>
	<brief_summary>This Phase 2a , multicenter , randomize , subject-blind , investigator-blind , study investigate pharmacokinetics ( PK ) , pharmacodynamics ( PD ) , safety bimekizumab adult subject moderate severe chronic plaque psoriasis</brief_summary>
	<brief_title>Study Evaluate Pharmacokinetics ( PK ) , Pharmacodynamics ( PD ) , Safety Bimekizumab Patients With Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Male female least 18 year age less equal 70 Chronic plaque psoriasis least 6 month prior Screening Psoriasis Area Severity Index ( PASI ) &gt; =12 body surface area ( BSA ) &gt; =10 % Investigator 's Global Assessment ( IGA ) score &gt; =3 5point scale Candidates systemic psoriasis therapy and/or phototherapy and/or chemophototherapy Female subject must postmenopausal , permanently sterilize , childbearing potential , must willing use highly effective method contraception till 20 week last administration study drug , negative pregnancy test Visit 1 ( Screening ) immediately prior first dose Male subject partner childbearing potential must willing use condom sexually active , till 20 week last administration study medication ( anticipated 5 halflives ) Subjects previously participate bimekizumab study Subjects erythrodermic , guttate , pustular form psoriasis , druginduced psoriasis History chronic recurrent infection , serious lifethreatening infection within 6 month prior Baseline Visit ( include herpes zoster ) High risk infection Investigator 's opinion Current sign symptom may indicate active infection Concurrent acute chronic viral hepatitis B C human immunodeficiency virus ( HIV ) infection Live ( include attenuate ) vaccination within 8 week prior Baseline Subjects concurrent malignancy history malignancy past 5 year ( except specific malignant condition define protocol ) Primary immunosuppressive condition TB infection , high risk acquire TB infection , latent TB infection ( LTBI ) , current history NTMB infection Laboratory abnormality , define study protocol Any condition , Investigator 's judgement , would make subject unsuitable inclusion study Exposure 1 biological response modifier ( limited antiTNF IL12/23 ) biologic response modifier three month prior Baseline Visit Subjects receive previous treatment antiIL17 therapy treatment psoriasis psoriatic arthritis Subjects diagnosis inflammatory condition psoriasis psoriatic arthritis , include limited rheumatoid arthritis , sarcoidosis , systemic lupus erythematosus . Subjects diagnosis Crohn 's disease ulcerative colitis allow long active symptomatic disease Screening Baseline Subjects take psoriatic arthritis medication nonsteroidal antiinflammatory drug ( NSAIDs ) analgesic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Chronic Plaque Psoriasis</keyword>
	<keyword>Bimekizumab</keyword>
</DOC>